ElevateBio Life Edit (R) is the Company's gene editing technologies and R&D business, focused on building the world's largest gene editing toolbox to expand addressable diseases and open a new ...

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of LENTICLAIR™ 1 ...

Cell and gene therapies have brought great advances to the treatment of severe diseases previously deemed untreatable. Despite commercial and clinical success of AAV-based gene therapies (seven ...

Adeno-associated viruses (AAV) have emerged as pivotal delivery vehicles for gene therapy due to their overall safety (less immunogenic), efficiency (broad tropism), and long-term gene expression.